PHARMACEUTICAL COMPOSITION FOR TREATING FLT3 MUTATION-POSITIVE CANCER, FLT3 MUTANT INHIBITOR, AND USE OF SAID PHARMACEUTICAL COMPOSITION AND SAID INHIBITOR
Problem of the present invention is that providing: pharmaceutical composition is for treating FLT3 mutation positive cancers A kind of FLT3 mutant inhibitor With a kind of using the Pharmaceutical composition and above-mentioned inhibitor. Provide: pharmaceutical composition is used to treat the positive malignant tumour of FLT3 mutation, the compound or its salt indicated containing the general formula [1] as active constituent A kind of FLT3 mutant inhibitor Anticancer agent A kind of pharmaceutical composition of administration that predicting curative effect, the object containing the compound or its salt that general formula [1] indicates, the method includes the steps: detect the presence of FLT3 mutation For select will with whom pharmaceutical composition, containing general formula [1] indicate compound or its salt can be applied to, the method includes the steps: detect the presence of FLT3 be mutated And a kind of determining pharmaceutical composition, the compound or its salt containing general formula [1] expression are administered to object, and the method includes the steps: detect the presence of FLT3 mutation.
